Literature DB >> 12353868

Successful surgery using recombinant factor VIIa for recurrent, idiopathic nonulcer duodenal bleeding in a patient with Glanzmann's thrombasthenia.

Henk R van Buuren1, Jenne J Wielenga.   

Abstract

A 68-year-old man with Glanzmann's thrombasthenia suffered from recurrent cryptogenic bleeding originating in the upper duodenal flexure. Extensive endoscopic procedures and medical treatments were unsuccessful and proximal duodenectomy was proposed. In preceding years platelet transfusions had often had a suboptimal result and were complicated by allergic reactions. Surgery was carried out while he was being treated with recombinant Factor VIIa. Neither major blood loss nor other complications occurred. Histological examination of the bleeding site failed to show abnormalities and the nature of this patient's bleeding problem remained unexplained. Glanzmann's thrombasthenia is a rare autosomal recessive disorder of platelet aggregation characterized by a lifelong bleeding tendency due to abnormalities of the glycoprotein IIb-IIIa membrane complex. Common clinical manifestations include purpuric type bleeding, epistaxis, menorrhagia and gingival bleeding. Spontaneous bleeding is uncommon but posttraumatic and postoperative hemorrhage may be particularly serious. There is no specific treatment. Prophylactic and therapeutic platelet transfusions are the cornerstone of supportive treatment. In many patients the efficacy of this approach is diminished by allo-anti-platelet antibodies. We report on a patient with Glanzmann's disease with recurrent nonulcer duodenal bleeding refractory to conservative medical treatment. Despite documented suboptimal effectiveness of platelet transfusions, he underwent successful surgery with administration of recombinant factor VIIa (rFVIIa).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12353868     DOI: 10.1023/a:1019605803467

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  14 in total

1.  Successful use of recombinant FVIIa (Novoseven) in the management of intractable post-surgical intra-abdominal haemorrhage.

Authors:  B White; J McHale; N Ravi; J Reynolds; R Stephens; J Moriarty; O P Smith
Journal:  Br J Haematol       Date:  1999-12       Impact factor: 6.998

2.  Treatment of traumatic bleeding with recombinant factor VIIa.

Authors:  G Kenet; R Walden; A Eldad; U Martinowitz
Journal:  Lancet       Date:  1999-11-27       Impact factor: 79.321

3.  Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII.

Authors:  A J Vlot; E Ton; A J Mackaay; M H Kramer; C A Gaillard
Journal:  Am J Med       Date:  2000-04-01       Impact factor: 4.965

4.  Successful treatment of massive hemoptysis in acute leukemia with recombinant factor VIIa.

Authors:  K Meijer; W E de Graaff; S M Daenen; J van der Meer
Journal:  Arch Intern Med       Date:  2000-07-24

Review 5.  The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia.

Authors:  D M Monroe; M Hoffman; G A Allen; H R Roberts
Journal:  Semin Thromb Hemost       Date:  2000       Impact factor: 4.180

6.  A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa.

Authors:  L Tengborn; B Petruson
Journal:  Thromb Haemost       Date:  1996-06       Impact factor: 5.249

7.  Effective treatment of severe bleeding due to acquired thrombocytopathia by single dose administration of activated recombinant factor VII.

Authors:  K Meijer; E Sieders; M J Slooff; J T de Wolf; J van der Meer
Journal:  Thromb Haemost       Date:  1998-07       Impact factor: 5.249

8.  Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors.

Authors:  J M Lusher
Journal:  Haemostasis       Date:  1996

9.  The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor.

Authors:  H ten Cate; K A Bauer; M Levi; T S Edgington; R D Sublett; S Barzegar; B L Kass; R D Rosenberg
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

10.  Platelet activity of high-dose factor VIIa is independent of tissue factor.

Authors:  D M Monroe; M Hoffman; J A Oliver; H R Roberts
Journal:  Br J Haematol       Date:  1997-12       Impact factor: 6.998

View more
  2 in total

Review 1.  The emerging role of recombinant-activated factor VII in neurocritical care.

Authors:  Matthew E Fewel; Paul Park
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

Review 2.  Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.

Authors:  Man-Chiu Poon
Journal:  Vasc Health Risk Manag       Date:  2007
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.